Saturday, June 27, 2020 9:02:57 AM
quote from stock twit board
$AIM
if Roswell PRs on this trial saying Ampligen has shown to be effective and safe in cancer patients with COVID-19 that these trials will be implemented in mass quantities in several countries. An EUA will be granted by the FDA...remember the 2 drugs that have already received it, which would you rather have if you were a 75 year old COVID-19, cancer and diabetic patient? Would you choose Remdesivir? How about hydroxychloroquine? Or Ampligen that has already been deemed safe and effective on the “train wreck COVID-19 cases”. Equels mentioned in May that the Roswell COVID-19 trials were a nice surprise. AIM didn’t do anything to initiate this which tells me Roswell already knows it’s effective and they stumbled across it by accident.
Equels has said in April interview that, “Ampligen could be the only effective treatment for SARS-CoV-2.”
Key takeaway as a shareholder, read the PR before you set a PT to sell at. If Roswell says it works our micro cap will become a mid cap!
$AIM
if Roswell PRs on this trial saying Ampligen has shown to be effective and safe in cancer patients with COVID-19 that these trials will be implemented in mass quantities in several countries. An EUA will be granted by the FDA...remember the 2 drugs that have already received it, which would you rather have if you were a 75 year old COVID-19, cancer and diabetic patient? Would you choose Remdesivir? How about hydroxychloroquine? Or Ampligen that has already been deemed safe and effective on the “train wreck COVID-19 cases”. Equels mentioned in May that the Roswell COVID-19 trials were a nice surprise. AIM didn’t do anything to initiate this which tells me Roswell already knows it’s effective and they stumbled across it by accident.
Equels has said in April interview that, “Ampligen could be the only effective treatment for SARS-CoV-2.”
Key takeaway as a shareholder, read the PR before you set a PT to sell at. If Roswell says it works our micro cap will become a mid cap!
Recent AIM News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 09:30:45 PM
- AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors • GlobeNewswire Inc. • 03/18/2026 12:36:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:30:12 PM
- AIM ImmunoTech Announces Closing of its Rights Offering • GlobeNewswire Inc. • 03/07/2026 12:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 10:15:32 PM
- AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million • GlobeNewswire Inc. • 03/04/2026 02:00:00 PM
- AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 03/02/2026 02:00:00 PM
- AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering • GlobeNewswire Inc. • 02/27/2026 02:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/27/2026 01:30:11 PM
- AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 • GlobeNewswire Inc. • 02/25/2026 02:00:00 PM
- AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 02/23/2026 01:55:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/17/2026 01:15:30 PM
- AIM ImmunoTech Announces Commencement of Rights Offering • GlobeNewswire Inc. • 02/12/2026 09:35:00 PM
- AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event • GlobeNewswire Inc. • 02/12/2026 01:55:00 PM
- AIM ImmunoTech Announces Commencement of Rights Offering • GlobeNewswire Inc. • 02/11/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/11/2026 05:15:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2026 10:03:20 PM
- AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial • GlobeNewswire Inc. • 02/06/2026 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:40:53 PM
- AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 02/05/2026 01:40:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/29/2026 09:31:00 PM
- AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering • GlobeNewswire Inc. • 01/27/2026 09:35:00 PM
- AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering • GlobeNewswire Inc. • 01/23/2026 06:22:21 PM
